8-K: Bellevue Life Sciences Secures $60,000 Loan from Sponsor Member

Bellevue Life Sciences Acquisition Corp. has issued a $60,000 promissory note to Josh Pan, a member of its sponsor, with repayment contingent on a business combination or a specified date.

Summary

• Bellevue Life Sciences Acquisition Corp. issued a $60,000 promissory note to Josh Pan on March 8, 2024.
• Josh Pan is a member of Bellevue Capital Management, LLC, which wholly owns the sponsor of the company.
• The note is unsecured and does not accrue interest.
• The principal is due on the earlier of August 8, 2024, or the date the company completes an initial business combination.
• The note will be forgiven if the company does not complete a business combination by the deadline in its charter, except for funds held outside the trust account.
• An event of default occurs if the company fails to pay within five business days of the due date or if bankruptcy proceedings commence.
• On March 12, 2024, $60,000 was deposited into the trust account to extend the business combination deadline from March 14, 2024, to April 15, 2024.

Sentiment

Score: 6

Explanation: The document is neutral, detailing a standard financial transaction for a SPAC. The loan is small and non-interest bearing, which is positive, but the repayment is contingent on a business combination, which introduces some risk.

Positives

• The company has secured a $60,000 loan to support operations.
• The loan is non-interest bearing, reducing the cost of capital.
• The loan is structured to align with the company's business combination timeline.

Negatives

• The loan is due relatively soon, either by August 8, 2024, or upon a business combination.
• Failure to repay the loan within five business days of the due date constitutes an event of default.
• The loan is dependent on the company's ability to complete a business combination.

Risks

• The company may face challenges in repaying the loan if a business combination is not completed by the deadline.
• The company's ability to complete a business combination is uncertain.
• The company could face default if it fails to repay the loan on time.

Future Outlook

The company's ability to repay the loan is contingent on completing a business combination by April 15, 2024, or the extended deadline. If no business combination is completed, the note will be forgiven, except for funds held outside the trust account.

Management Comments

• The company's CEO, Kuk Hyoun Hwang, signed the promissory note on behalf of Bellevue Life Sciences Acquisition Corp.

Industry Context

This is a common practice for SPACs to obtain short-term funding from their sponsors or related parties to cover operational expenses while seeking a business combination. The structure of the loan, with forgiveness tied to the business combination, is also typical.

Comparison to Industry Standards

• Many SPACs use similar short-term, non-interest bearing loans from sponsors to cover operating costs.
• The forgiveness clause tied to the business combination is a standard feature in these types of loans.
• The amount of the loan, $60,000, is relatively small compared to the overall capital raised by the SPAC, which is typical for these types of bridge loans.

Related Party Transactions

• The promissory note was issued to Josh Pan, a member of Bellevue Capital Management, LLC, which wholly owns the sponsor of the company.

Stakeholder Impact

• Shareholders are impacted by the extension of the business combination deadline.
• The loan provides short-term funding for the company's operations.
• The loan terms are structured to align with the company's business combination timeline.

Next Steps

• The company needs to complete a business combination by April 15, 2024, to avoid potential issues with the promissory note.
• The company will need to monitor the progress of the business combination and ensure compliance with the terms of the promissory note.

Key Dates

Keywords

promissory note, business combination, SPAC, loan, Bellevue Life Sciences, Josh Pan, trust account, default, sponsor